You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 18, 2024

CLINICAL TRIALS PROFILE FOR FLUZOPARIB


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Fluzoparib

Trial ID Title Status Sponsor Phase Summary
NCT02575651 ↗ A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies Completed 307 Hospital of PLA Phase 1 Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
NCT02575651 ↗ A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies Completed Beijing Cancer Hospital Phase 1 Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
NCT02575651 ↗ A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies Completed Jiangsu HengRui Medicine Co., Ltd. Phase 1 Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of Fluzoparib will be investigated.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Fluzoparib

Condition Name

Condition Name for
Intervention Trials
Ovarian Cancer 7
Small Cell Lung Cancer 3
Breast Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Breast Neoplasms 12
Ovarian Neoplasms 10
Carcinoma, Ovarian Epithelial 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluzoparib

Trials by Country

Trials by Country for
Location Trials
China 49
Australia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluzoparib

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 6
Phase 2 21
Phase 1/Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 19
Not yet recruiting 18
Completed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluzoparib

Sponsor Name

Sponsor Name for
Sponsor Trials
Jiangsu HengRui Medicine Co., Ltd. 28
Fudan University 7
Tianjin Medical University Cancer Institute and Hospital 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 32
Other 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.